Comparison of Vascular Perturbations in an A β‐Injected Animal Model and in AD Brain
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The validity of amyloid‐β peptide (A β1–42) intrahippocampal injection, as an animal model of Alzheimer′s disease (AD), has previously been considered in terms of inflammatory reactivity and neuronal damage. In this work, we have extended the testing of the animal model to vasculature by comparison of selected properties of microvessels in vivo with those in human AD brain tissue. The injection of A β1–42, relative to control PBS (phosphate buffered saline), increased the mean number of microvessels and diminished the mean length of microvessels in the molecular layer of dentate gyrus. The animal model showed A β1–42, but not PBS, injection was associated with abnormalities in morphology of microvessels which were characterized as looping, fragmented, knob‐like, uneven, and constricted. In particular, numbers of constricted microvessels, defined as vessels with diameters less than 3 μ m, were considerably enhanced for A β1–42, compared to PBS, injection. In comparison, human AD brain demonstrated an elevated number of microvessels with a diminished mean length relative to nondemented (ND) brain. Additionally, microvessel perturbations in AD brain showed a similar pattern of morphological abnormalities to those observed in A β1–42‐injected rat hippocampus. Constricted microvessels were a prominent feature of AD brain but were rarely observed in ND tissue. These results provide the first evidence that a peptide‐injection animal model exhibits a commonality in perturbations of microvessels compared with those evident in AD brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 2×
“SAGE-Hindawi Access to Research International Journal of Alzheimer’s Disease Volume 2011, Article ID 918280, 8 pages doi:10.4061/2011/918280 Research Article Comparison of Vascular Perturbations in an Aβ-Injected Animal Model and in AD Brain Nattinee Jantaratnotai,1, 2 Jae K. Ryu,1 Claudia Schwab,3 Patrick L. McGeer,3…”
BackgroundInfluentialMicroglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 1×
“broad spectrum of altered properties from those of control nondemented (ND) individuals including the presence of enhanced deposits of amyloid-β peptide (Aβ) [1], neurofibrillary tangles (NFTs) [2], abnormalities in vasculature [3–5], evidence for ongoing chronic inflammation [6, 7], and loss of neurons and synaptic c…”
BackgroundMicrovascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Ryu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406 · cited 5×
“Combined with measurements on BBB dysfunction [12], the Aβ1−42 animal model has demonstrated efficacy in simulating prominent vasculature changes evident in diseased tissue.”
BackgroundMethodResultSelf-citationMicroglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
Tarkowski, E., Issa, R., Sjögren, M., Wallin, A., Blennow, K., Tarkowski, A., & Kumar, P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00285-8 · Cited by 360
McLarnon, J. G., Ryu, J. K., Walker, D. G., & Choi, H. B. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240470.97295.d3 · Cited by 281
Self-citationEvidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153 · cited 1×
“Although increased expressions of laminin [20, 21] and integrin αvβ3 [22, 23] have been suggested as indicators of angiogenesis they are not specific markers which differentiate between newly formed and existing capillaries.”
Background
Cited by
Chen, J.-H., Ke, K.-F., Lu, J.-H., Qiu, Y.-H., & Peng, Y.-P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116549 · Cited by 151
Thomas, R., Zuchowska, P., Morris, A. W. J., Marottoli, F. M., Sunny, S., Deaton, R., Gann, P. H., & Tai, L. M. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0387-3 · Cited by 72
Tajiri, N., Kellogg, S. L., Shimizu, T., Arendash, G. W., & Borlongan, C. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078851 · Cited by 70
“Vascular damage caused by TBI may play a critical role in the exacerbation of AD-like histopathology following TBI as seen in laboratory [29,30] and clinical studies [29–33].”
BackgroundNoh, J.-E., Oh, S.-H., Park, I.-H., & Song, J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.546659 · Cited by 28
Borbély, E., Horváth, J., Furdan, S., Bozsó, Z., Penke, B., & Fülöp, L. (2014) · BioMed Research International · doi:10.1155/2014/345305 · Cited by 21
Metadata
- Authors
- Jantaratnotai, N., Ryu, J. K., Schwab, C., McGeer, P. L., & McLarnon, J. G.
- Venue
- International Journal of Alzheimer’s Disease
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 2011
- Issue
- 1
- Pages
- 918280-918280
- ISSN
- 2090-0252 (ISSN-L)
- 2090-8024
- OpenAlex
- W2115764559
- Cited by
- 33
- References
- 12
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.